全文获取类型
收费全文 | 23091篇 |
免费 | 1425篇 |
国内免费 | 41篇 |
专业分类
耳鼻咽喉 | 152篇 |
儿科学 | 719篇 |
妇产科学 | 740篇 |
基础医学 | 2944篇 |
口腔科学 | 308篇 |
临床医学 | 3680篇 |
内科学 | 3860篇 |
皮肤病学 | 216篇 |
神经病学 | 2423篇 |
特种医学 | 414篇 |
外科学 | 2013篇 |
综合类 | 274篇 |
一般理论 | 32篇 |
预防医学 | 3411篇 |
眼科学 | 328篇 |
药学 | 1468篇 |
中国医学 | 26篇 |
肿瘤学 | 1549篇 |
出版年
2024年 | 15篇 |
2023年 | 154篇 |
2022年 | 234篇 |
2021年 | 432篇 |
2020年 | 292篇 |
2019年 | 455篇 |
2018年 | 550篇 |
2017年 | 413篇 |
2016年 | 465篇 |
2015年 | 560篇 |
2014年 | 767篇 |
2013年 | 1147篇 |
2012年 | 1678篇 |
2011年 | 1837篇 |
2010年 | 956篇 |
2009年 | 863篇 |
2008年 | 1574篇 |
2007年 | 1714篇 |
2006年 | 1590篇 |
2005年 | 1576篇 |
2004年 | 1579篇 |
2003年 | 1442篇 |
2002年 | 1420篇 |
2001年 | 238篇 |
2000年 | 165篇 |
1999年 | 195篇 |
1998年 | 270篇 |
1997年 | 228篇 |
1996年 | 166篇 |
1995年 | 179篇 |
1994年 | 162篇 |
1993年 | 124篇 |
1992年 | 114篇 |
1991年 | 91篇 |
1990年 | 84篇 |
1989年 | 76篇 |
1988年 | 67篇 |
1987年 | 70篇 |
1986年 | 43篇 |
1985年 | 71篇 |
1984年 | 59篇 |
1983年 | 50篇 |
1982年 | 60篇 |
1981年 | 58篇 |
1980年 | 36篇 |
1979年 | 24篇 |
1978年 | 28篇 |
1977年 | 23篇 |
1976年 | 19篇 |
1975年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
Frédéric Janvier Deborah Delaune Thomas Poyot Eric Valade Audrey Mérens Pierre E. Rollin Vincent Foissaud 《Emerging infectious diseases》2016,22(2):292-294
We evaluated RNA stability of Ebola virus in EDTA blood and urine samples collected from infected patients and stored in West Africa’s environmental conditions. In blood, RNA was stable for at least 18 days when initial cycle threshold values were <30, but in urine, RNA degradation occurred more quickly. 相似文献
7.
8.
9.
Emmi Helle Aldo Córdova-Palomera Tiina Ojala Priyanka Saha Praneetha Potiny Stefan Gustafsson Erik Ingelsson Michael Bamshad Deborah Nickerson Jessica X. Chong University of Washington Center for Mendelian Genomics Euan Ashley James R. Priest 《Genetic epidemiology》2019,43(2):215-226
Loss of function variants in NOTCH1 cause left ventricular outflow tract obstructive defects (LVOTO). However, the risk conferred by rare and noncoding variants in NOTCH1 for LVOTO remains largely uncharacterized. In a cohort of 49 families affected by hypoplastic left heart syndrome, a severe form of LVOTO, we discovered predicted loss of function NOTCH1 variants in 6% of individuals. Rare or low-frequency missense variants were found in 16% of families. To make a quantitative estimate of the genetic risk posed by variants in NOTCH1 for LVOTO, we studied associations of 400 coding and noncoding variants in NOTCH1 in 1,085 cases and 332,788 controls from the UK Biobank. Two rare intronic variants in strong linkage disequilibrium displayed significant association with risk for LVOTO amongst European-ancestry individuals. This result was replicated in an independent analysis of 210 cases and 68,762 controls of non-European and mixed ancestry. In conclusion, carrying rare predicted loss of function variants in NOTCH1 confer significant risk for LVOTO. In addition, the two intronic variants seem to be associated with an increased risk for these defects. Our approach demonstrates the utility of population-based data sets in quantifying the specific risk of individual variants for disease-related phenotypes. 相似文献
10.
Toshio Kushiro Hiroshige Itakura Yoshihisa Abo Hiromi Gotou Shinji Terao Deborah L Keefe 《Hypertension research》2006,29(12):997-1005
Aliskiren is a novel orally active renin inhibitor for the treatment of hypertension. This study evaluated the antihypertensive efficacy, safety and tolerability of aliskiren in Japanese patients with hypertension. Forty hundred and fifty-five Japanese men and women with a mean sitting diastolic blood pressure of 95-110 mmHg were randomized to receive once-daily double-blind treatment for 8 weeks with aliskiren 75, 150 or 300 mg or placebo. Aliskiren produced significant, dose-dependent reductions in mean sitting diastolic blood pressure (p<0.0005 vs. placebo for each dose) and mean sitting systolic blood pressure (p<0.001 vs. placebo for each dose). The placebo-corrected reductions in mean sitting systolic/diastolic blood pressure were 5.7/4.0, 5.9/4.5 and 11.2/7.5 mmHg in the aliskiren 75, 150 and 300 mg groups, respectively. After 8 weeks' treatment, 27.8%, 47.8%, 48.2% and 63.7% of patients in the placebo and aliskiren 75, 150 and 300 mg groups, respectively, achieved a successful treatment response (diastolic blood pressure <90 mmHg and/or reduced by > or =10 mmHg from baseline; p<0.005 vs. placebo for each dose). Aliskiren treatment was well tolerated, with the incidence of adverse events reported in the active treatment groups (53-55%) being similar to that in the placebo group (50%). This study, which is the first to assess the antihypertensive efficacy and safety of aliskiren in Japanese patients with hypertension, demonstrates that the once-daily oral renin inhibitor aliskiren provides significant, dose-dependent reductions in blood pressure with placebo-like tolerability. 相似文献